THE INTERSECTION OFINTERVENTIONAL ONCOLOGY& IMMUNO-ONCOLOGY
Immunophotonics is a biotech company developing a proprietary polymer that turns a common local tumor ablation into a systemic immunotherapy for cancer.
We are a multidisciplinary team of highly experienced individuals committed to pioneering the future of cancer immunotherapy.
We have subsidiaries in Bern, Switzerland (IPS Biopharma developing IP-001 for the European market.) and Tianjin, China (YiNuo developing IP-001 for the Chinese market).